Drug-provoked Psoriasis: is It Drug Induced or Drug Aggravated?: Understanding Pathophysiology and Clinical Relevance

Overview

Journal J Clin Aesthet Dermatol

Date 2010 Aug 21

PMID 20725536

Citations 41

Authors

Grace K Kim

James Q Del Rosso

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a commonly encountered dermatosis with a variety of internal and external paradoxical factors contributing to the clinical course of the disease. There are several drugs described in the literature that have been associated with the initiation, exacerbation, and aggravation of psoriasis. Understanding the pathophysiology can provide clues to treatment and management of drug-induced and drug-aggravated psoriasis, which may be indistinguishable from idiopathic psoriasis. The clinical manifestations of drug-associated psoriasis can range from plaque-type psoriasis to severe erythroderma, thus warranting astute and sustained clinical observation.

Citing Articles

Pharmacotherapy of arterial hypertension in patients with psoriasis.

Dodulik J, Dodulikova L, Plasek J, Ramik Z, Vrtal J, Vaclavik J J Hypertens. 2025; 43(4):568-576.

PMID: 39976197 PMC: 11872270. DOI: 10.1097/HJH.0000000000003982.

A case of probable drug-induced psoriasis to dapagliflozin.

Qureshi S, Finch S, Pratt M SAGE Open Med Case Rep. 2024; 12:2050313X241284003.

PMID: 39618702 PMC: 11605749. DOI: 10.1177/2050313X241284003.

The Role of Vitamin D3 Deficiency and Colonization of the Oral Mucosa by Yeast-like Fungi in the Pathomechanism of Psoriasis.

Marchlewicz M, Sagan P, Grabowska M, Kiedrowicz M, Kruk J, Gill K J Clin Med. 2024; 13(22).

PMID: 39598018 PMC: 11594318. DOI: 10.3390/jcm13226874.

Bedaquiline-induced psoriasiform drug eruption in a patient of multidrug-resistant tuberculosis.

Kowe P, Zatakia S, Chethan M, Dhurat R Indian J Pharmacol. 2024; 56(3):228-230.

PMID: 39078190 PMC: 11286095. DOI: 10.4103/ijp.ijp_49_24.

Ruptured abdominal aortic aneurysm in psoriasis: A case report and review of literature.

Mouhanni S, Hassani A, Lekehal M, Bounssir A, Bakkali T, Lekehal B Int J Surg Case Rep. 2024; 120:109829.

PMID: 38870660 PMC: 11225200. DOI: 10.1016/j.ijscr.2024.109829.

References

Forster S, Ilderton E, Summerly R, Yardley H . The level of phospholipase A2 activity is raised in the uninvolved epidermis of psoriasis. Br J Dermatol. 1983; 108(1):103-5. DOI: 10.1111/j.1365-2133.1983.tb04585.x. View

Sarantidis D, Waters B . A review and controlled study of cutaneous conditions associated with lithium carbonate. Br J Psychiatry. 1983; 143:42-50. DOI: 10.1192/bjp.143.1.42. View

Wolf R, Lo Schiavo A . Is transglutaminase the mediator between antimalarial drugs and psoriasis?. Int J Dermatol. 1997; 36(1):10-3. DOI: 10.1046/j.1365-4362.1997.00002.x. View

Akkerhuis G, Nolen W . Lithium-associated psoriasis and omega-3 fatty acids. Am J Psychiatry. 2003; 160(7):1355. DOI: 10.1176/appi.ajp.160.7.1355. View

Puig L, Goni F, Roque A, Bordas F, de Moragas J . Psoriasis induced by ophthalmic timolol preparations. Am J Ophthalmol. 1989; 108(4):455-6. DOI: 10.1016/s0002-9394(14)73322-7. View

Raftery E, DENMAN A . Systemic lupus erythematosus syndrome induced by practolol. Br Med J. 1973; 2(5864):452-5. PMC: 1589475. DOI: 10.1136/bmj.2.5864.452. View

Sidoroff A, Halevy S, Bavinck J, Vaillant L, Roujeau J . Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol. 2001; 28(3):113-9. DOI: 10.1034/j.1600-0560.2001.028003113.x. View

ASSEM E, Banks R . Practolol-induced drug eruption. Proc R Soc Med. 1973; 66(2):179-81. PMC: 1644525. View

Abel E, DiCicco L, Orenberg E, Fraki J, Farber E . Drugs in exacerbation of psoriasis. J Am Acad Dermatol. 1986; 15(5 Pt 1):1007-22. DOI: 10.1016/s0190-9622(86)70265-x. View

10.

Gill R, Mohammed F, Badyal R, Coates L, Erskine P, Thompson D . High-resolution structure of myo-inositol monophosphatase, the putative target of lithium therapy. Acta Crystallogr D Biol Crystallogr. 2005; 61(Pt 5):545-55. DOI: 10.1107/S0907444905004038. View

11.

Waqar S, Sarkar P . Exacerbation of psoriasis with beta-blocker therapy. CMAJ. 2009; 181(1-2):60. PMC: 2704418. DOI: 10.1503/cmaj.081433. View

12.

Tsankov N, Angelova I, Kazandjieva J . Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol. 2001; 1(3):159-65. DOI: 10.2165/00128071-200001030-00003. View

13.

DiGiovanna J, Aoyagi T, Taylor J, HALPRIN K . Inhibition of epidermal adenyl cyclase by lithium carbonate. J Invest Dermatol. 1981; 76(4):259-63. DOI: 10.1111/1523-1747.ep12526094. View

14.

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

15.

Sehgal V, Dogra S, Srivastava G, Aggarwal A . Psoriasiform dermatoses. Indian J Dermatol Venereol Leprol. 2008; 74(2):94-9. DOI: 10.4103/0378-6323.39688. View

16.

Skoven I, Thormann J . Lithium compound treatment and psoriasis. Arch Dermatol. 1979; 115(10):1185-7. View

17.

Hu C, Miller A, Peppercorn R, Farber E . Generalized pustular psoriasis provoked by propranolol. Arch Dermatol. 1985; 121(10):1326-7. View

18.

Beyaert R, Schulze-Osthoff K, VAN Roy F, Fiers W . Synergistic induction of interleukin-6 by tumor necrosis factor and lithium chloride in mice: possible role in the triggering and exacerbation of psoriasis by lithium treatment. Eur J Immunol. 1992; 22(8):2181-4. DOI: 10.1002/eji.1830220835. View

19.

Kuflik E . Effect of antimalarial drugs on psoriasis. Cutis. 1980; 26(2):153-5. View

20.

Hwang S, Ahn S, Menon G, Choi E, Lee S . Basis of occlusive therapy in psoriasis: correcting defects in permeability barrier and calcium gradient. Int J Dermatol. 2001; 40(3):223-31. DOI: 10.1046/j.1365-4362.2001.01158.x. View